FrancophonIA/ELRC3.0 huggingface dataset:
English: Warnings regarding renal impairment, concomitant therapy with an ACE inhibitor in heart failure, haemodialysis, renal artery stenosis, kidney transplantation, hypotension, anaesthesia and surgery, aortic and mitral valve stenosis, primary hyperaldosteronism and hyperkalaemia were harmonised.
Maltese: Kienu armonizzati twissijiet fir-rigward ta' indeboliment renali, terpija konkomittanti ma' inibitur ACE f'kollass tal-qalb, emodijaliżi, stenożi arterjali renali, trapjant tal-kliewi, pressjoni baxxa, anesteżija u kirurġija, stenożi aortali u tal-valvola mitrijali, iperaldosteroniżmu primarju u iperkalaemiija.
English: Very rare Back pain, arthralgia, myalgia
Maltese: Rari ħafna Uġigħ fid-dahar, artralġja, mijalġja
English: Very rare Nausea
Maltese: Rari ħafna Iponatrimija
English: • Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac,
Maltese: • Mediċini anti-infjammatorji mhux sterojdi bħal ibuprofen, naproxen, diclofenac, celecoxib, jew etoricoxib (mediċini li jnaqqsu l-uġigħ u l-infjammazzjoni)
English: The trough blood pressure reduction (systolic/diastolic) was 13.1/10.5 mmHg with candesartan cilexetil 32 mg once daily and 10.0/8.7 mmHg with losartan potassium 100 mg once daily (difference in blood pressure reduction 3.1/1.8 mmHg, p<0.0001/p<0.0001).
Maltese: 0/8.7 mm Hg b'losartan potassju 100 mg mogħti darba kuljum (differenza fit-tnaqqis tal-pressjoni 3.1/1.8 mmHg, p<0.0001/p<0.0001).
English: Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.020).
Maltese: Kura b'candesartan cilexetil wasslet għal titjib fil-klassi funzjonali ta' NYHA (p=0.020).
English: This is also confirmed in the recent meta-analysis by Law et al 2009, based on randomised trials.
Maltese: Dan huwa kkonfermat ukoll minn meta-analiżi riċenti ta' Law et al 2009, ibbażata fuq provi każwali.
English: Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin.
Maltese: Candesartan ma jimpedixxix ACE, li jikkonverti angiotensin I f'angiotensin II u jkisser il-bradykinin.
English: Atacand is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3 and 5.2).
Maltese: Atacand huwa kontraindikat f'pazjenti b'indeboliment qawwi tal-fwied u/jew b'kolestasi (ara sezzjonijiet 4.3 u 5.2).
English: No gender related differences in the pharmacokinetics of candesartan have been observed.
Maltese: Ma kienu osservati l-ebda differenzi relatati mas-sess fil-farmakokinetika ta' candesartan.
English: The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients with mild to moderate hypertension.
Maltese: L-effett ta' kontra l-pressjoni u t-tollerabilita ta' candesartan u losartan tqabblu f'żewġ studji randomised u double blind f'total ta' 1,268 pazjent bi pressjoni minn ħafifa sa moderata.
English: In the PostMarketing sub-section, the frequency “Very Rare” was replaced with the frequency “not known” as, for post marketing experience the frequency could not be estimated in accordance with the guideline on the SPC (September 2009).
Maltese: Fis-sub-sezzjoni ta' Wara t-Tqegħid fis-Suq, il-frekwenza “Rari Ħafna” ġiet mibdula bil-frekwenza “mhux magħruf” minħabba li, f'esperjenza ta' wara t-tqegħid fis-suq, il-frekwenza ma setgħetx tiġi stmata u skont illinji ta' gwida fl-SPC (Settembru 2009).
English: Withdrawals from treatment due to adverse events were similar with candesartan cilexetil (3.1%) and placebo (3.2%).
Maltese: It-twaqqif tal-kura minħabba każijiet avversi kien jixxiebah b'candesartan cilexetil (3.1%) u bi plaċebo (3.2%).
English: In individual case reports of overdose (of up to 672 mg candesartan cilexetil) patient recovery was uneventful.
Maltese: F'rapporti ta' każijiet individwali ta' doża eċċessiva (sa 672 mg ta' candesartan cilexetil) il-fejqan tal-pazjent kien ordinarju.
English: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Maltese: Pazjenti bi problemi ereditarji rari ta' intolleranza għall-galactose, defiċjenza ta' Lapp lactase jew malassorbiment ta' glucose-galactose m'għandhomx jieħdu dan il-prodott mediċinali.
English: Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg.
Maltese: It-tneħħija totali ta' candesartan mill-plażma hija ta' madwar 0.37 ml/min/kg, bi tneħħija mill-kliewi ta' madwar 0.19 ml/min/kg.
English: Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Maltese: Tqala u treddigħ (ara sezzjoni 4.6).
English: When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Maltese: (i.e. impedituri selettivi ta' COX-2, acetylsalicylic acid (> 3 g/jum) u NSAIDs mhux selettivi), jista' jseħħ tnaqqis fl-effett ta' kontra l-pressjoni.
English: Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.008).
Maltese: Kura b'candesartan cilexetil wasslet għal titjib fil-klassi funzjonali ta' NYHA (p=0.008).
English: In general, there were no clinically important influences of Atacand on routine laboratory variables.
Maltese: B'mod ġenerali, ma kien hemm l-ebda influwenzi ta' importanza klinika ta' Atacand fuq varjabbli tallaboratorju ta' rutina.
English: ANNEX I
Maltese: Basiglio (MI)
English: Atacand contains candesartan cilexetil, an angiotensin receptor blocker (ARB), indicated for the treatment of essential hypertension in adults and of adult patients with heart failure and impaired left ventricle systolic function (left ventricular ejection fraction  40%) as add-on therapy to Angiotensin Converting Enzyme (ACE inhibitors) or when ACE inhibitors are not tolerated.
Maltese: Atacand fih candesartan cilexetil, immblokkatur tar-riċetturi ta' angiotensin (ARB), indikat għall-kura ta' pressjoni għOlja essenzjali fl-adulti u ta' pazjenti adulti b'kollass tal-qalb u b'funzjoni sistolika indebolita tal-ventrikola tax-xellug (frazzjoni ta' tfigħ ventrikulari tax-xellug  40%) bħala terapija miżjuda għall-Enzżima li Tikkonverti Angiotensin (inibituri ACE) jew meta l-inibituri ACE mhumiex tollerati.
English: The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).
Maltese: L-Użu ta' AIIRAs huwa kontraindikat waqt it-tieni u t-tielet trimestri tat-tqala (ara sezzjoni 4.3 u 4.4)
English: There were 26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk 0.89, 95%CI 0.75 to 1.06, p=0.19).
Maltese: sena tal-pazjenti fil-grupp ta' candesartan versus 30.0 każ għal kull 1000 sena tal-pazjenti fil-grupp ta' kontroll (riskju relattiv 0.89, 95%CI 0.75 sa 1.06, p=0.19).
English: • Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤ 40%) as add-on therapy to Angiotensin Converting Enzyme (ACE) inhibitors or when ACE inhibitors are not tolerated (see section 5.1).
Maltese: • Għall-kura ta' pazjenti adulti b'insuffiċjenza tal-qalb u funzjoni sistolika indebolita talventrikulu tax-xellug (frazzjoni ta' tfigħ 'il barra mill-ventrikulu tax-xellug ≤ 40%) bħala terapija addizzjonali ma' impedituri ta' Angiotensin Converting Enzyme (ACE) jew meta impedituri ACE ma jkunux ittollerati (ara sezzjoni 5.1).
English: Treatment with candesartan cilexetil reduces mortality, reduces hospitalisation due to heart failure, and improves symptoms in patients with left ventricular systolic dysfunction as shown in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Maltese: Kura b'candesartan cilexetil tnaqqas il-mortalità, tnaqqas id-dħul fl-isptar minħabba insuffiċjenza talqalb, u ttejjeb sintomi f'pazjenti b'disfunzjoni sistolika tal-ventrikulu tax-xellug kif intwera filprogramm Candesartan f'insuffiċjenza tal-Qalb - Stima tat-Tnaqqis fil-Mortalità u l-morbidità (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM)).
English: The beneficial effects of candesartan were consistent irrespective of age, gender and concomitant medication.
Maltese: L-effetti ta' ġid ta' candesartan kienu konsistenti irrispettivament mill-età, mis-sess u mill-mediċina konkomitanti.
English: Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).
Maltese: Huwa magħruf li esponiment għall- kura b' AIIRA waqt it-tieni u t-tielet trimestri tikkawża tossiċita tal-fetu uman (tnaqqis tal-funzjoni renali, oligoidramnios, ossifikazzjoni tal-kranju retardata) u tossiċita neonata (insuffiċjenza renali, pressjoni baxxa, livell għoli ta' potassju) (ara sezzjoni 5.3).
English: CARTON FOR BLISTER / CARTON FOR BOTTLE / LABEL FOR BOTTLE
Maltese: KARTUNA GĦALL-FOLJA/KARTUNA GĦALL-FLIXKUN/TIKKETTA GĦALL-FLIXKUN
English: Atacand 16, tabletten 16 mg 16 mg Tablet
Maltese: Atacand 16, tabletten 16 mg 16 mg
English: Atacand 32, tabletten 32 mg 32 mg Tablet
Maltese: Atacand 32, tabletten 32 mg 32 mg
English: The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.
Maltese: L-antagoniżmu tar-riċetturi ta' angiotensin II (AT1) iwassal għal żidiet relatati maddoża fil-livelli ta' renin fil-plażma, fil-livelli ta' angiotensin I u angiotensin II, u fi tnaqqis talkonċentrazzjoni ta' aldosterone fil-plażma.
English: Of candesartan patients 42.2% (95%CI: 39.5 to 45.0) and of placebo patients 46.1% (95%CI: 43.4 to 48.9) experienced this endpoint, absolute difference 3.9% (95%CI: 7.8 to 0.1).
Maltese: 39.5 sa 45.0) u mill-pazjenti li ħadu plaċebo 46.1% (95%CI: 43.4 sa 48.9) esperjenzaw dan il-punt aħħari, differenza assoluta ta' 3.9% (95%CI: 7.8 sa 0.1).
English: Finland AstraZeneca Oy Luomanportti 3
Maltese: AstraZeneca Oy Luomanportti 3 FI-02200 Espoo Finland
English: Mon Tue Wed Thur Fri Sat Sun
Maltese: M'għandekx tgħaddiha lill persuni oħra.
English: Parapres 16 mg comprimidos
Maltese: Parapres 16 mg comprimidos 16 mg
English: Results from two clinical studies investigating the pharmacokinetic (PK) profile of candesartan in patients with impaired hepatic function and the publication by Hoogkamer et al 1998, where a starting dose of 12 mg was used, indicate that mild to moderate hepatic impairment has no relevant effect on candesartan PK, and thus no dose adjustment is required.
Maltese: Riżultati minn żewġ studji kliniċi li investigaw il-profil farmakokinetiku (PK) ta' candesartan f'pazjenti b'funzjoni epatika indebolita u l-pubblikazzjoni minn Hoodkamer et al 1998, fejn intużat doża tal-bidu ta' 12 mg, jindikaw li indeboliment epatiku żgħir jew moderat ma għandux effett relevanti fuq il-PK ta' candesartan, u għalhekk ma huwa meħtieġ l-ebda aġġustament fid-doża.
English: After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target dose of 32 mg.
Maltese: Wara 6 xhur ta' kura 63% tal-pazjenti li kienu għadhom qed jieħdu candesartan cilexetil (89%) kienu fid-doża ta' 32 mg li kienet id-doża fil-mira.
English: Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.
Maltese: Prodotti mediċinali li jaffettwaw is-sistema ta' renin-angiotensin-aldosterone, li jinkludu l-antagonisti tar-riċetturi ta' angiotensin II (AIIRAs), jistgħu jżidu l-urea fid-demm u l-krejatinina fis-serum f'pazjenti li għandhom stenożi bilaterali tal-arterji tal-kilwa jew li għandhom stenożi tal-arterja lejn kilwa unika.
English: In particular, updates on the potential dose increase up to 32 mg, increased antihypertensive effect when candesartan is combined with other medicinal products, including hydrochlorothiazide and CCB such as amlodipine or felodipine were considered.
Maltese: B'mod partikolari, kienu kkunsidrati aġġornamenti dwar iż-żieda potenzjali tad-doża sa 32 mg, żieda fl-effett kontra l-pressjoni għolja meta candesartan tiġi kkombinata ma' prodotti mediċinali oħrajn, inklużi hydrochlorothiazide u CCB bħal amlodipine jew felodipine.
English: Common (affects 1 to 10 users in 100)
Maltese: Komuni (jaffettwaw minn 1 sa 10 minn kull 100 li jużawh)
English: C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.
Maltese: Wara doża mill-ħalq ta' candesartan cilexetil tikkettat b'14C, madwar 26% mid-doża titneħħa fl-awrina bħala candesartan u 7% titneħħa bħala lmetabolit mhux attiv filwaqt li madwar 56% mid-doża hija rkuprata mill-ippurgar bħala candesartan u 10% tiġi rkuprata bħala l-metabolit mhux attiv.
English: • Heparin (a medicine for thinning the blood).
Maltese: • Hepraina (mediċina sabiex traqqaq id-demm)
English: There is limited experience in patients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min) (see section 4.4).
Maltese: Hemm esperjenza limitata f'pazjenti b'indeboliment tal-kliewi qawwi ħafna jew tal-ahħar stadju (Clcreatinine < 15 ml/min) (ara sezzjoni 4.4).
English: Concomitant therapy with an ACE inhibitor in heart failure The risk of adverse reactions, especially renal function impairment and hyperkalaemia, may increase when Atacand is used in combination with an ACE inhibitor (see section 4.8).
Maltese: Terapija konkomitanti b'impeditur ta' ACE f'insuffiċjenza tal-qalb Ir-riskju ta' reazzjonijiet avversi, speċjalment indeboliment fil-funzjoni tal-kliewi u iperkalimja, jistgħu jiżdiedu meta Atacand jintuża flimkien ma' impeditur ta' ACE (ara sezzjoni 4.8).
English: Atacand 32 mg - Tabletten 32 mg Tablet
Maltese: Atacand 32 mg - Tabletten 32 mg
English: Patients who receive such combination therapy require careful and regular monitoring.
Maltese: Pazjenti li jirċievu tali kombinazzjoni ta' terapija jeħtieġu kontroll regolari u b'kawtela.
English: There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction).
Maltese: Ma kien hemm l-ebda differenzi sinifikanti b'mod statistiku fl-aħħar punt primarju, li kienu każijiet kardjovaskulari serji (mortalità kardjovaskulari, puplesija mhux fatali, u infart mijokardijaku mhux fatali).
English: The recent ESH guidelines (Mancia et al 2007) and the Joint National Committee (JNC) VII guidelines (Chobanian et al 2003) for the treatment of hypertension state that the benefit may be substantial even when blood pressure reductions are small, and the initial blood pressure is below the traditional cut off defining hypertension.
Maltese: Il-linji gwida riċenti ta' ESH (Mancia et al 2007) u l-linji gwida tal-Kumitat Nazzjonali Konġunt (KNK) VII (Chobanian et al 2003) għall-kura ta' pressjoni għolja jistqarru li lbenefiċċju jista' jkun sostanzjali anke meta t-tnaqqis fil-pressjoni tad-demm ikun żgħir, u l-pressjoni tad-demm inizjali tkun taħt dik li tradizzjonaliment tiddefinixxi l-pressjoni għolja.
English: It is acknowledged that there is limited data in this population, however, analysis of the primary composite endpoint, cardiovascular death or hospitalisation due to heart failure by NYHA class subgroups in the low EF trials (CHARMAlternative and CHARM-Added pooled, part of the CHARM programme), revealed Hazard Ratios (HR) below 1.0 in favour of candesartan compared to placebo in each of the NYHA subgroups.
Maltese: Huwa rikonoxxut li hemm dejta limitata f'din il-popolazzjoni, madankollu, l-analiżi tal-punt finali kompost primarju, il-mewt kardjovaskular jew rikoveru l-isptar minħabba kollass tal-qalb minn subgruppi ta' klassi NYHA filprovi ta' EF baxxi (CHARM-Alternattiv u CHARM-Miżjud miġburin), uriet Proporzjonijiet ta' Periklu (HR) taħt 1.0 favur candesartan meta mqabbla ma' plaċebo f'kull wieħed mis-subgruppi ta' NYHA.
English: Atacand 16 mg - Tabletten 16 mg Tablet
Maltese: Atacand 16 mg - Tabletten 16 mg
English: • Skin rash, lumpy rash (hives).
Maltese: • Raxx fil-ġilda, raxx bil-boċċi (ħorriqija)
English: BEFORE YOU TAKE ATACAND
Maltese: X'INHU ATACAND
English: Blopress 32 mg - Tabletten 32 mg Tablet
Maltese: Blopress 32 mg - Tabletten 32 mg
English: System Organ Class
Maltese: KLASSIFIKA ĠENERALI
English: Blopress 16 mg Tabletten 16 mg Tablet
Maltese: Blopress 16 mg Tabletten 16 mg
English: The relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with very little variability.
Maltese: Il-bijodisponibiltà relattiva tal-formulazzjoni tal-pillola mqabbla mal-istess soluzzjoni orali hija ta' madwar 34% bi ftit li xejn varjabbilità.
English: Blopress 32 mg Tabletten 32 mg Tablet
Maltese: Blopress 32 mg Tabletten 32 mg
English: Blopress 16 mg - Tabletten 16 mg Tablet
Maltese: Blopress 16 mg - Tabletten 16 mg
English: Anaesthesia and surgery
Maltese: Anestesija u kirurġija
English: • if you have a disease of the adrenal gland called Conn's syndrome (also called primary hyperaldosteronism).
Maltese: • Jekk għandek mard tal-glandola adrenali tissejjaħ sindrome Cronn's (tissejjaħ ukoll iperaldosteronismu primarja)
English: Patients on optimal CHF therapy at baseline were randomised to placebo or candesartan cilexetil (titrated from 4 mg or 8 mg once daily to 32 mg once daily or the highest tolerated dose, mean dose 24 mg) and followed for a median of 37.7 months.
Maltese: Pazjenti bl-aħjar kura possibbli għal CHF fil-linja bażi kienu randomised għal plaċebo jew għal candesartan cilexetil (doża miżjuda ftit ftit minn 4 mg jew 8 mg darba kuljum għal 32 mg darba kuljum jew l-ogħla doża ttollerata, doża medja ta' 24 mg) u ġew segwiti għal medjan ta' 37.7 xhur.
English: Based on the information provided, the CHMP endorsed the harmonised text for Angiotensin II receptor antagonists as the standard warning elaborated by the CHMP's Pharmacovigilance Working Party for all Angiotensin II receptor antagonists (AIIRAs): the use of AIIRAs in the first trimester of pregnancy is not recommended; the use of AIIRAs in the second and third trimester is contraindicated.
Maltese: Fuq il-bażi tal-informazzjoni pprovduta, is-CHMP awtorizza test armonizzat ta' antagonisti tarriċetturi Angiotensin II bħala twissija standard elaborata mill-Parti ta' Ħidma għall-Farmakoviġilanza għall-antagonisti tar-riċetturi ta' Angiotensin II kollha (AIIRAs): l-użu ta' AIIRAs fl-ewwel trimestru tat-tqala mhuwiex irrikkomandat; l-użu ta' AIIRAs fit-tieni u t-tielet trimestru huwa kontra-indikat.
English: Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system.
Maltese: Pressjoni baxxa tista' sseħħ waqt l-anestesija u l-kirurġija f'pazjenti kkurati b'antagonisti ta' angiotensin II minhabba imblokk tas-sistema ta' renin-angiotensin.
English: In the elderly (over 65 years) Cmax and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects.
Maltese: Fl-anzjani (li għandhom aktar minn 65 sena) is-Cmax u l-AUC ta' candesartan jiżdiedu b'madwar 50% u 80%, rispettivament speċjalment meta mqabbla ma' individwi żgħar.
English: There is limited experience in patients with very severe or end-stage renal impairment (Clcreatinine < 15 ml/min).
Maltese: Hemm esperjenza limitata f'pazjenti b'indeboliment tal-kliewi qawwi ħafna jew tal-aħħar stadju (Clkrejatinina < 15 ml/min).
English: In patients with impaired hepatic function, the initial starting dose was changed from 2 mg to 4 mg.
Maltese: F'pazjenti b'funzjoni epatika indebolita, id-doża tal-bidu inizjali ġiet mibdula minn 2 mg għal 4 mg.
English: Parapres 32 mg comprimidos
Maltese: Parapres 32 mg comprimidos 32 mg
English: Sweden AstraZeneca AB 151 85 Södertälje, Sweden
Maltese: AstraZeneca AB 151 85 Södertälje, Sweden
English: In CHARM-Added, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, HR 0.85 (95%CI: 0.75 to 0.96, p=0.011).
Maltese: F'CHARM-Added, il-punt aħħari mlaqqa' għall-mortalità minn kawżi kardjovaskulari jew l-ewwel dħul l-isptar minħabba CHF tnaqqas b'mod sinifikanti b'candesartan meta mqabbel ma' plaċebo, HR 0.85 (95%CI: 0.75 sa 0.96, p=0.011).
English: Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9).
Maltese: Il-biċċa l-kbira ta' candesartan jitneħħa mhux mibdul mal-awrina u l-bila u xi ftit biss minnu jiġi eliminat permezz ta' metaboliżmu epatiku (CYP2C9).
English: Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion.
Maltese: Effetti fuq il-kliewi (bħal nefrite tal-interstizju, nefħa tubulari, tubuli bażofiliċi, żieda fil-konċentrazzjonijiet tal-urea u lkrejatinina fil-plażma) kienu kkaġunati minn candesartan li jistgħu jkunu ġejjin minħabba l-effett ta' pressjoni baxxa li jwassal għal tibdil fil-perfużjoni tal-kilwa.
English: In patients with CHF and depressed left ventricular systolic function (left ventricular ejection fraction, LVEF  40%), candesartan decreases systemic vascular resistance and pulmonary capillary wedge pressure, increases plasma renin activity and angiotensin II concentration, and decreases aldosterone levels.
Maltese: F'pazjenti b'CHF u b'funzjoni sistolika ventrikulari tax-xellug mnaqqsa (frazzjoni ta' tfigħ 'il barra mill-ventrikulu tax-xellug, LVEF  40%), candesartan inaqqas ir-reżistenza sistemika vaskulari u lpressjoni minn feles kapillari fil-pulmun, iżid l-attività tar-renin u l-konċentrazzjoni ta' angiotensin II fil-plażma, u jnaqqas il-livelli ta' aldosterone.
English: An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see section 4.4).
Maltese: Doża inizjali ta' 4 mg tista' titqies f'pazjenti li għandhom riskju ta' pressjoni baxxa, bħal pazjenti li jistgħu jkollhom tnaqqis fil-volum (ara sezzjoni 4.4).
English: During dialysis the blood pressure may be particularly sensitive to AT1-receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system.
Maltese: Waqt id-dijalisi l-pressjoni tista' tkun partikolarment sensittiva għal imblokk tar-riċettur AT1 minħabba tnaqqis fil-volum tal-plażma u l-attivazzjoni tas-sistema tar-renin-angiotensin-aldosterone.
English: No clinically significant pharmacokinetic interactions with these medicinal products have been identified.
Maltese: Ma kienu identifikati l-ebda interazzjonijiet farmakokinetiċi sinifikanti ma' dawn il- prodotti medicinali.
English: Atacand 16 mg comprimidos
Maltese: Atacand 16 mg comprimidos 16 mg
English: Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Atacand.
Maltese: Iż-żieda ta' hydrochlorothiazide intweriet li jkollha effett addittiv kontra l-pressjoni ma'dożi varji ta' Atacand.
English: Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension, heart failure and other cardiovascular disorders.
Maltese: Angiotensin II huwa l-ormon primarju vażoattiv tas-sistema ta' renin-angiotensin-aldosterone u għandu rwol fil-patofiżjoloġija tal-pressjoni għolja, tal-insuffiċjenza tal-qalb u ta' disturbi kardjovaskulari oħra.